Literature DB >> 15154623

Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer.

Markku Santala1, Juha Risteli, Antti Kauppila.   

Abstract

BACKGROUND: The clinical significance of the carboxyterminal telopeptide of type I (ICTP) as a predictor of prognosis is insufficiently known in ovarian cancer. Therefore, we compared the prognostic accuracy of ICTP and CA 125 and their combination with each other and with the aminoterminal propeptide of type III procollagen (PIIINP) and clinical prognosticators. PATIENTS AND METHODS: Fifty-five epithelial ovarian cancer patients treated in Oulu University Hospital, Finland, from 1989-1995, were enrolled in this study. Cytoreduction was performed as completely as possible. The preoperative serum concentrations of the biochemical markers were determined using commercial kits.
RESULTS: In univariate analysis, each biochemical marker and all conventional prognostic indicators, with the exception of histological subtype, correlated significantly with survival. In multivariate Cox analysis on biochemical and clinical markers, ICTP alone and ICTP + CA 125, but not CA 125 alone, proved useful indicators of overall survival. The combination of ICTP and CA 125, however, added no essential information compared to that obtained with ICTP alone.
CONCLUSION: The ICTP test seems to be a clinically useful predictor of the clinical behavior of ovarian cancer. An increased serum ICTP concentration may reflect the spreading and aggressiveness of invasively growing ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154623

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

2.  Methodology and applications of disease biomarker identification in human serum.

Authors:  Ziad J Sahab; Suzan M Semaan; Qing-Xiang Amy Sang
Journal:  Biomark Insights       Date:  2007-02-14

3.  Collagen Type III Metabolism Evaluation in Patients with Malignant Head and Neck Cancer Treated with Radiotherapy.

Authors:  Klaudia Mazurek; Krzysztof Siemianowicz; Wirginia Likus; Ewa Pierzchała; Robert Kwiatkowski; Jarosław Markowski
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

4.  Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.

Authors:  Qingyi Wang; Xiaoling Feng; Xiaofang Liu; Siyu Zhu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.